IRIS

Breccia, M., Fianchi, L., Lunghi, M., Gaidano, G., Levis, A., Finelli, C., et al. (2013). Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. LEUKEMIA & LYMPHOMA, 54(8), 1786-1787 [10.3109/10428194.2012.749406].

Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine

VOSO, MARIA TERESA
2013-08-01
ago-2013
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Antimetabolites, Antineoplastic; Azacitidine; Humans; Myelodysplastic Syndromes; Neoplasms, Second Primary; Treatment Outcome
Breccia, M., Fianchi, L., Lunghi, M., Gaidano, G., Levis, A., Finelli, C., et al. (2013). Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. LEUKEMIA & LYMPHOMA, 54(8), 1786-1787 [10.3109/10428194.2012.749406].
Breccia, M; Fianchi, L; Lunghi, M; Gaidano, G; Levis, A; Finelli, C; Santini, V; Musto, P; Mansueto, G; Oliva, E; Leoni, P; Spiriti, M; Hohaus, S; Leo...espandi
Articolo su rivista
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/118306
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact